Form 4: Halozyme Therapeutics Director Sells Shares
Insider Transaction (Form 4)
Matthew L. Posard, a Director of Halozyme Therapeutics, Inc., sold 5,230 shares of common stock on October 1, 2026.
Summary
- Open-market sale: disposed of 730 Common Stock at $107.17 ($78,233) on October 1, 2026; holds 58,109 after (Direct).
- Open-market sale: disposed of 3,300 Common Stock at $108.45 ($357,898) on October 1, 2026; holds 54,809 after (Direct).
- Open-market sale: disposed of 1,100 Common Stock at $109.57 ($120,526) on October 1, 2026; holds 53,709 after (Direct).
- Open-market sale: disposed of 100 Common Stock at $110.04 ($11,004) on October 1, 2026; holds 53,609 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $567,661 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Matthew L. Posard — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-01 | Open-market sale | Common Stock | 730 | $107 | $78.2K | 58,109 |
| 2026-10-01 | Open-market sale | Common Stock | 3,300 | $108 | $357.9K | 54,809 |
| 2026-10-01 | Open-market sale | Common Stock | 1,100 | $110 | $120.5K | 53,709 |
| 2026-10-01 | Open-market sale | Common Stock | 100 | $110 | $11.0K | 53,609 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-01 | Open-market sale (730 shares) |
| 2026-10-01 | Open-market sale (3,300 shares) |
| 2026-10-01 | Open-market sale (1,100 shares) |
| 2026-10-01 | Open-market sale (100 shares) |
Keywords
insider transaction, Form 4, HALO, HALOZYME THERAPEUTICS, INC., bearish, Matthew L. Posard
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.